EMA resolves dispute over pricey Canary Wharf tenancyAfter months of wrangling, the EMA finally has a solution to the £500 million financial liability it has Share XEMA resolves dispute over pricey Canary Wharf tenancyhttps://pharmaphorum.com/news/ema-resolves-dispute-over-pricey-canary-wharf-tenancy/
Alexion’s Soliris follow-up Ultomiris snares EU approvalAlexion has the EU approval it needed for Ultomiris, a follow-up to its rare disease therapy Soliris that Share XAlexion’s Soliris follow-up Ultomiris snares EU approvalhttps://pharmaphorum.com/news/alexions-soliris-follow-up-ultomiris-snares-eu-approval/
Mitsubishi Tanabe pulls ALS drug from EMA assessmentMitsubishi Tanabe Pharma has withdrawn its EU application for ALS drug Radicava (edaravone), citing ‘unwarranted’ additional data requirements Share XMitsubishi Tanabe pulls ALS drug from EMA assessmenthttps://pharmaphorum.com/news/mitsubishi-tanabe-pulls-als-drug-from-ema-assessment/
EMA set for official move from London on 1 MarchThe European Medicines Agency (EMA) has officially taken over its new building in Amsterdam in preparation of its Share XEMA set for official move from London on 1 Marchhttps://pharmaphorum.com/news/ema-set-official-move-london/
UK drugs regulator consults on ‘no deal’ Brexit arrangementsDespite the government insisting that Brexit will have no negative fallout, the UK’s drugs regulator is consulting on Share XUK drugs regulator consults on ‘no deal’ Brexit arrangementshttps://pharmaphorum.com/news/uk-drugs-regulator-consults-on-no-deal-brexit-arrangements/
Europe’s CHMP regulatory committee has new chairEurope’s top drugs regulatory committee has a new leader after Dr Tomas Salmonson stepped down as chair of Share XEurope’s CHMP regulatory committee has new chairhttps://pharmaphorum.com/news/europes-chmp-regulatory-committee-has-new-chair/
EMA freezes UK representatives out of drug reviews as Brexit loomsThe UK’s drugs regulator is increasingly being frozen out of work with the European Medicines Agency (EMA) according Share XEMA freezes UK representatives out of drug reviews as Brexit loomshttps://pharmaphorum.com/news/ema-freezes-uk-representatives-out-of-drug-reviews-as-brexit-looms/
Neurofibromatosis treatment granted orphan status by EMAAstraZeneca and Merck & Co. announced the European Medicines Agency (EMA) has granted orphan designation to their codeveloped Share XNeurofibromatosis treatment granted orphan status by EMAhttps://pharmaphorum.com/news/nf1-treatment-granted-orphan-status-ema/
EMA warns Brexit move will cause higher-than-expected staff lossesEurope’s medicines regulator is expecting higher-than-anticipated staff departures as a result of its Brexit-induced move from London to Share XEMA warns Brexit move will cause higher-than-expected staff losseshttps://pharmaphorum.com/news/ema-brexit-staff-losses-amsterdam/
